HsMAD2 mRNA expression may be a predictor of sensitivity to paclitaxel and survival in neuroblastoma
- 133 Downloads
We investigated the associations between hsMAD2 mRNA expression in tumor cells and sensitivity to paclitaxel or patient prognosis in neuroblastoma.
Fifty-one formalin-fixed paraffin-embedded tumor samples were manually microdissected to collect tumor cells, and RNA was purified. Nineteen clinical samples of advanced neuroblastoma showed appropriate quality of the isolated RNA for real-time reverse transcription-polymerase chain reaction (RT-PCR) analyses. The hsMAD2 expression levels were determined by real-time RT-PCR in 4 neuroblastoma cell lines and 19 clinical samples. The sensitivity to paclitaxel was assessed by WST-8 colorimetric assays and flow cytometry. HsMAD2 expression of the clinical samples was investigated for its association with prognosis in advanced neuroblastoma patients.
There was a significant positive correlation between hsMAD2 mRNA expression and the sensitivity to paclitaxel in four neuroblastoma cell lines. High hsMAD2 expression may be correlated with paclitaxel-induced apoptosis. Kaplan–Meier survival curves were stratified by hsMAD2 expression using the median value as a cut-off point and analyzed for prognostic significance by the log-rank test (P = 0.0467). Furthermore, multivariate survival analysis revealed that only hsMAD2 expression had a significant impact on the overall survival rate.
Our results may warrant clinical application of paclitaxel in neuroblastoma treatment for poor prognosis patients.
KeywordsNeuroblastoma HsMAD2 Paclitaxel Gene expression Predictor
Conflict of interest
Authors declare no potential financial disclosure or conflict of interest.
- 7.Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C (2004) Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430(7001):797–802. doi: 10.1038/nature02820 CrossRefPubMedGoogle Scholar
- 9.Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, Smith EI, London WB, Castleberry R (2004) Response to paclitaxel, topotecan, and topotecan–cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study. J Clin Oncol 22(20):4119–4126. doi: 10.1200/JCO.2004.08.174 CrossRefPubMedGoogle Scholar
- 12.Tanaka K, Mohri Y, Ohi M, Yokoe T, Koike Y, Morimoto Y, Miki C, Tonouchi H, Kusunoki M (2008) Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol) 20(8):639–646. doi: 10.1016/j.clon.2008.06.010 Google Scholar
- 23.Ramanathan RK, Rubin JT, Ohori NP, Belani CP (2000) Dramatic response of adult wilms tumor to paclitaxel and cisplatin. Med Pediatr Oncol 34(4):296–298. doi: 10.1002/(SICI)1096-911X(200004)34:4<296:AID-MPO20>3.0.CO CrossRefPubMedGoogle Scholar
- 25.Li Z, Zhang J, Liu Z, Woo CW, Thiele CJ (2007) Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death. Cell Death Differ 14(2):318–326. doi: 10.1038/sj.cdd.4401983 CrossRefPubMedGoogle Scholar